PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
This article was originally published in The Pink Sheet Daily
Privately held biotech announces an additional $23 million raise from existing investors to finance a head-to-head Phase IIb trial for its GLP-1 analogue against Victoza.
You may also be interested in...
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.